Alfa Cytology is a specialized provider of comprehensive radionuclide drug conjugate (RDC) preclinical development services, dedicated to advancing targeted radiotherapy through expert design, conjugation, and analysis. Backed by an extensive library of radionuclides, chelators, and linkers, we deliver end-to-end solutions tailored to your unique therapeutic objectives, from early-stage concept exploration to preclinical development support.
Learn More
Alfa Cytology provides comprehensive radiolabeling services leveraging a diverse portfolio of radionuclides, including key isotopes like 177Lu, 68Ga, 18F, and many others. Our capabilities cover isotope conjugation, purification, and quality control, ensuring precise labeling efficiency and stability. With a focus on flexibility and scalability, we provide customized radiolabeling solutions for peptides, antibodies, and small molecules.
Learn More
Alfa Cytology delivers specialized RDC binding analysis to accelerate your drug discovery and development. Our radioligand binding assays deliver precise, quantitative characterization of receptor-ligand interactions, including binding affinity, binding capacity, and dissociation kinetics. We employ advanced techniques to evaluate binding specificity, competition, and allosteric modulation, providing the critical data needed for drug development.
Learn More
